全文获取类型
收费全文 | 29431篇 |
免费 | 6870篇 |
国内免费 | 146篇 |
学科分类
医药卫生 | 36447篇 |
出版年
2024年 | 137篇 |
2023年 | 1120篇 |
2022年 | 372篇 |
2021年 | 771篇 |
2020年 | 1297篇 |
2019年 | 619篇 |
2018年 | 1470篇 |
2017年 | 1411篇 |
2016年 | 1650篇 |
2015年 | 1715篇 |
2014年 | 2177篇 |
2013年 | 2701篇 |
2012年 | 1230篇 |
2011年 | 1206篇 |
2010年 | 1657篇 |
2009年 | 2204篇 |
2008年 | 1188篇 |
2007年 | 963篇 |
2006年 | 1116篇 |
2005年 | 855篇 |
2004年 | 744篇 |
2003年 | 732篇 |
2002年 | 641篇 |
2001年 | 564篇 |
2000年 | 458篇 |
1999年 | 548篇 |
1998年 | 618篇 |
1997年 | 577篇 |
1996年 | 632篇 |
1995年 | 459篇 |
1994年 | 370篇 |
1993年 | 329篇 |
1992年 | 315篇 |
1991年 | 302篇 |
1990年 | 290篇 |
1989年 | 263篇 |
1988年 | 257篇 |
1987年 | 231篇 |
1986年 | 245篇 |
1985年 | 217篇 |
1984年 | 165篇 |
1983年 | 186篇 |
1982年 | 138篇 |
1981年 | 129篇 |
1979年 | 110篇 |
1978年 | 91篇 |
1977年 | 102篇 |
1976年 | 87篇 |
1974年 | 86篇 |
1973年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
3.
4.
5.
Kenny P. Pang FRCSEd FRCSI Claudio Vicini MD Filippo Montevecchi MD Ottavio Piccin MD MSc Sudipta Chandra MBBS MS Hyung C. Yang MD PhD Vikas Agrawal MS DLO Joseph C. K. Chung FRCS Yiong H. Chan BSc PhD Scott B. Pang Kathleen A. Pang Edward B. Pang Brian Rotenberg MD MPH FRCSC 《The Laryngoscope》2020,130(9):2281-2284
6.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献7.
8.
9.
10.
Stephanie Kay Kolar 《Addiction Research & Theory》2016,24(1):25-31
Aims: Relapse rates among cigarette smokers are high. Few studies have examined time-to-relapse using survival analysis in racially/ethnically diverse smokers and initial abstinence criteria have been inconsistent or unspecified. This study compared survival curves using two common definitions of initial abstinence. We hypothesized greater relapse rates among participants abstinent for only 24 hours (h) at the end-of-therapy (EOT) compared with 7 days. Methods: Adult smokers (59% Black, 22% Hispanic and 17% White) received 8-sessions of group cognitive behavioural therapy (CBT) plus transdermal nicotine patches and were assessed monthly up to 12 months post-EOT. Participants reporting abstinence (7-day point prevalence abstinence [ppa] or 24-h ppa) at the EOT were included in Kaplan–Meier curves. Results: Of 301 participants, 120 (40%) reported 7-day ppa at the EOT and an additional 29 (10%) reported 24-h ppa only. Over the 12-month follow-up period, nearly 50% remained abstinent. Of those who resumed smoking, most relapses occurred within the first three months. Survival curves indicated that median survival was 207 and 225 days for 7-day and 24-h definitions of abstinence, respectively. The difference in time-to-relapse between participants abstinent for 24?h at the EOT versus 7-days was not significant (p?=?0.14). Conclusions: Operationalization of initial abstinence is important for relapse analyses and comparisons of survival curves across samples. Participants reported high rates of abstinence and relapse rates were relatively low. Contrary to expectations, 24-h ppa at the EOT was not associated with greater relapse than 7-day abstinence. This suggests either measure may be utilized in relapse prevention research in racially/ethnically diverse treatment-seekers. 相似文献